Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier
Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier
复制标题
DOI：
10.1093/annonc/mdp230
复制
发表时间：
2009-12-01
影响因子：
50.5
通讯作者：
Sueoka, E.
中科院分区：
文献类型：
--
作者：
Fukushima, N.;Mizuta, T.;Sueoka, E.
Patients and methods: Forty-eight of 127 (37.8%) lymphoma patients were HBsAg negative and HBcAb positive, and 24 of these patients were then given liver function tests and HBsAg tests monthly and serum HBV DNA every 3 months.Results: HBV reactivation was observed in two patients (4.1%) who had received intensive chemotherapy including steroid and rituximab. Immediate administration of entecavir therapy after elevation of HBV DNA level was conducted, and this resulted in reduction of it and improvement of liver function test.Conclusions: Rituximab plus steroid-containing regimens may increase the risk of HBV reactivation in HBsAg-negative and HBcAb-positive lymphoma patients. More ambitious prospective studies are required to establish clinically useful or cost-effective follow-up methods for control of HBV reactivation in lymphoma patients with occult HBV infection.
